Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) CEO Eric D. Shaff sold 12,726 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total value of $10,308.06. Following the transaction, the chief executive officer now owns 192,039 shares of the company's stock, valued at $155,551.59. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Seres Therapeutics Stock Performance
Shares of MCRB stock opened at $0.83 on Thursday. Seres Therapeutics, Inc. has a 52 week low of $0.54 and a 52 week high of $1.53. The company's 50 day moving average price is $0.84 and its two-hundred day moving average price is $0.85. The company has a market capitalization of $141.68 million, a P/E ratio of -3.61 and a beta of 2.11.
Analysts Set New Price Targets
MCRB has been the topic of several recent analyst reports. JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a "neutral" rating to an "underweight" rating in a research note on Thursday, October 24th. Chardan Capital reiterated a "buy" rating and issued a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday, November 13th. Canaccord Genuity Group reissued a "buy" rating and issued a $10.00 price target on shares of Seres Therapeutics in a report on Thursday, November 14th. Finally, StockNews.com raised Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Seres Therapeutics presently has an average rating of "Hold" and a consensus target price of $5.08.
Read Our Latest Stock Analysis on Seres Therapeutics
Institutional Investors Weigh In On Seres Therapeutics
Large investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. acquired a new position in Seres Therapeutics in the 3rd quarter worth $374,000. Charles Schwab Investment Management Inc. boosted its position in shares of Seres Therapeutics by 42.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 748,718 shares of the biotechnology company's stock worth $708,000 after buying an additional 222,771 shares during the period. FMR LLC grew its holdings in shares of Seres Therapeutics by 0.6% during the third quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company's stock worth $21,625,000 after buying an additional 140,096 shares in the last quarter. Providence Wealth Advisors LLC grew its holdings in shares of Seres Therapeutics by 29.2% during the third quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company's stock worth $93,000 after buying an additional 22,250 shares in the last quarter. Finally, State Street Corp raised its position in Seres Therapeutics by 12.9% in the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after buying an additional 43,700 shares during the last quarter. Institutional investors own 59.34% of the company's stock.
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
